Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Regulator Tightens Drug Price-Control Loopholes

This article was originally published in PharmAsia News

Executive Summary

India's drug-pricing authority warns pharmaceutical companies they need approval before they can introduce new drugs containing ingredients that are under price controls. The National Pharmaceutical Pricing Authority changed its guidelines to tighten controls on companies using loopholes to avoid price controls. The new guidelines are intended to crack down on repeat offenders, so the second move to avoid price controls is to result in automatic prosecution, instead of waiting for several rounds of hearings and other moves before action is taken. (Click here for more

You may also be interested in...



E-cigarette NRT Outlook Heated By Combining With Counseling, Nicotine-Tapering Strategy

Results of three-year study conducted at 17 Canadian sites suggest that e-cigarettes use combined with counseling significantly increased abstinence from smoking cigarettes compared to receiving counseling alone.

Cambridge Nutraceuticals Targets Over 50s With UK Acquisition

Cambridge Nutraceuticals - which develops dietary supplements that have “proven clinical benefits” - has snapped up UK-based Prime Fifty to enhance its offering with products specifically designed for the over 50s.

Henlius Kicks Off Denosumab Trial

Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar version of denosumab. Multiple biosimilar developers are vying to take a slice of the market for rivals to Amgen’s Xgeva/Prolia original.

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel